SCHEMBL5024271

SCHEMBL5024271

O=C1Cn2ccnc2N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16353275 0.80 CRBN (0.40)
SCHEMBL18366453 0.77 CRBN (0.37)
SCHEMBL999429 0.69 ADRA1A (0.32)
SCHEMBL8272672 0.68 GAA (0.34)
SCHEMBL11170068 0.68 BRD4 (0.42)
SCHEMBL9267374 0.68 KDR (0.46)
SCHEMBL20719687 0.67
SCHEMBL11173756 0.66
SCHEMBL8088424 0.66
SCHEMBL25421399 0.65 CRBN (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210854-A1 MONO- AND COMBINATION THERAPIES RECURIUM IP HOLDINGS, LLC 2023-07-06 US disclosed
US-20230008362-A1 COMBINATIONS RECURIUM IP HOLDINGS, LLC 2023-01-12 US disclosed
CN-111032659-B Imidazo [1, 2-a ] imidazol-2-one derivatives for the treatment of diseases such as parkinson's disease 豪夫迈·罗氏有限公司 2022-09-09 CN disclosed
CN-111032659-B Imidazo [1, 2-a ] imidazol-2-one derivatives for the treatment of diseases such as parkinson's disease 豪夫迈·罗氏有限公司 2022-09-09 CN disclosed
US-20220024939-A1 SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES RECURIUM IP HOLDINGS, LLC 2022-01-27 US disclosed
EP-3668873-A1 IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE H. Hoffnabb-La Roche Ag (CH) 2020-06-24 EP disclosed
US-10590083-B2 Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2020-03-17 US disclosed
US-10399944-B2 Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-09-03 US disclosed
US-10336701-B2 Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2019-07-02 US disclosed
WO-2019034713-A1 IMIDAZO[1,2-A]IMIDAZOL-2-ONE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS PARKINSON'S DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2019-02-21 WO disclosed
EP-2445909-B1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INT (DE) 2013-11-13 EP disclosed
US-8575360-B2 Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-05 US disclosed
US-8481750-B2 Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-09 US disclosed
US-20120252817-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-04 US disclosed
US-20120178734-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-12 US disclosed
US-7314940-B2 For therapy and prophylaxis of neurodegenerative disorders related to apoptosis and/or inflammation EISAI CO., LTD. (JP) 2008-01-01 US disclosed
EP-1373269-B1 JUN KINASE INHIBITORS EISAI CO LTD (JP) 2005-06-08 EP disclosed
US-20040235864-A1 Jun kinase inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2004-11-25 US disclosed
EP-1373269-A1 JUN KINASE INHIBITORS Eisai Co., Ltd. (JP) 2004-01-02 EP disclosed
WO-2002081475-A1 JUN KINASE INHIBITORS EISAI CO., LIMITED (JP) 2002-10-17 WO disclosed